• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Obinutuzumab for B-cell malignancies
【24h】

Obinutuzumab for B-cell malignancies

机译：Obinutuzumab用于B细胞恶性肿瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: We analyse data for the use of obinutuzumab in the treatment of CD20+ lymphoproliferative disorders with a focus on chronic lymphocytic leukaemia (CLL). Targeted therapy against CD20 with the mAb rituximab led to significant improvements in survival for patients with B-cell non-Hodgkin lymphoma (NHL) and is the current mainstay of treatment for CD20+ malignancies. Despite this, many patients relapse or become refractory after rituximab-containing therapies, so efforts have been made to develop better anti-CD20 mAbs. Obinutuzumab recently demonstrated superiority over rituximab in the only published Phase III study comparing the two antibodies.Areas covered: Obinutuzumab is a humanised, anti-CD20 mAb being compared to rituximab in several Phase III studies. An overview of obinutuzumab, its mechanisms of action and results of Phase I-III studies are presented.Expert opinion: The demonstration of superiority of obinutuzumab over rituximab in the CLL11 Phase III study is potentially practice-changing. Obinutuzumab has also proven safe and efficacious in CD20+ NHL in Phase I/II studies and results of Phase III studies in NHL are eagerly awaited. The potential implications of improved outcomes for CLL and NHL with the introduction of this more potent anti-CD20 antibody are tremendous given the impressive results obtained after the introduction of rituximab over a decade ago.
机译：简介：我们分析了奥比妥珠单抗在治疗CD20 +淋巴增生性疾病中的应用数据，重点是慢性淋巴细胞性白血病（CLL）。利妥昔单抗单抗CD20的靶向治疗可显着提高B细胞非霍奇金淋巴瘤（NHL）患者的生存率，并且是CD20 +恶性肿瘤目前的治疗手段。尽管如此，许多患者在接受利妥昔单抗治疗后复发或变得难治，因此已努力开发出更好的抗CD20 mAb。 Obinutuzumab最近在唯一发表的比较这两种抗体的III期研究中证明了优于rituximab的研究领域：Obinutuzumab是一种人源化的抗CD20 mAb，在多项III期研究中与rituximab进行了比较。概述了奥比妥珠单抗，其作用机理以及I-III期研究的结果。专家意见：在CLL11 III期研究中，奥比妥珠单抗相对于利妥昔单抗的优越性可能会改变实践。在I / II期研究中，Obinutuzumab在CD20 + NHL中也被证明是安全有效的，因此人们迫切期待在NHL中进行III期研究的结果。鉴于在十年前引入利妥昔单抗后获得了令人印象深刻的结果，通过引入这种更有效的抗CD20抗体改善CLL和NHL的预后可能产生巨大的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号